The average one-year price target for Capricor Therapeutics (NasdaqCM:CAPR) has been revised to $51.82 / share. This is an increase of 32.98% from the prior estimate of $38.96 dated December 3, 2025.
The price target is an average of many targets provided by analysts. The latest targets range from a low of $41.41 to a high of $65.10 / share. The average price target represents an increase of 86.32% from the latest reported closing price of $27.81 / share.
What is the Fund Sentiment?
There are 230 funds or institutions reporting positions in Capricor Therapeutics. This is an decrease of 10 owner(s) or 4.17% in the last quarter. Average portfolio weight of all funds dedicated to CAPR is 0.03%, an increase of 47.33%. Total shares owned by institutions increased in the last three months by 4.09% to 16,724K shares. 
The put/call ratio of CAPR is 2.95, indicating a bearish outlook.
What are Other Shareholders Doing?
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 1,234K shares representing 2.39% ownership of the company. In its prior filing, the firm reported owning 1,190K shares , representing an increase of 3.58%. The firm decreased its portfolio allocation in CAPR by 3.18% over the last quarter.
IWM - iShares Russell 2000 ETF holds 964K shares representing 1.86% ownership of the company. In its prior filing, the firm reported owning 996K shares , representing a decrease of 3.29%. The firm increased its portfolio allocation in CAPR by 2.28% over the last quarter.
Geode Capital Management holds 962K shares representing 1.86% ownership of the company. In its prior filing, the firm reported owning 963K shares , representing a decrease of 0.16%. The firm decreased its portfolio allocation in CAPR by 64.95% over the last quarter.
VEXMX - Vanguard Extended Market Index Fund Investor Shares holds 658K shares representing 1.27% ownership of the company. In its prior filing, the firm reported owning 658K shares , representing a decrease of 0.12%. The firm decreased its portfolio allocation in CAPR by 6.05% over the last quarter.
XBI - SPDR(R) S&P(R) Biotech ETF holds 586K shares representing 1.13% ownership of the company. In its prior filing, the firm reported owning 1,017K shares , representing a decrease of 73.40%. The firm decreased its portfolio allocation in CAPR by 36.09% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
